Dr. Reddy's Laboratories
RDY
12.27
-0.22
-1.76%
Dr. Reddy's Laboratories
US · RDY
#1451 by market cap
Listed 1970
12.27
-0.22
-1.76%
Live - 5344 symbols - heartbeat 372s ago
· 2026-10-08 08:11
Pre-market
12.27
0.00%
After-hours
12.27
0.00%
- Market cap
- 10.22B
- P/E (TTM)i
- 29.93
- P/Bi
- 2.58
- EPSi
- 0.53
- Div yieldi
- 0.69%
- 52W posi
- 23%
Reader sentiment
Are you bullish or bearish on RDY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.7 percentage points.
Institutional ownership
- Held by institutions
- 60.25% -2.71pp
- Institutions
- 402 -6
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund40.97%
Individual/Insider26.73%
Public Company13.12%
Hedge Fund2.37%
Private Company1.00%
Sovereign Wealth Fund0.85%
Government Pension Fund0.78%
Government0.64%
Corporate Pension Plan0.29%
Other13.26%
Top holders as of 2026-03-31
Kallam Reddy
13.61% · 113.38M sh
Gunupati Prasad
13.07% · 108.91M sh
Life Insurance Corporation of India
12.19% · 101.50M sh
ICICI Prudential Asset Management Company Limited
5.05% · 42.05M sh
BlackRock
4.03% · 33.56M sh
Vanguard Capital Management, LLC
3.11% · 25.92M sh
PPFAS Asset Management Private Limited
2.91% · 24.23M sh
Boston Partners Global Investors, Inc.
2.17% · 18.04M sh
RBC Global Asset Management Inc.
1.88% · 15.68M sh
Nippon Life India Asset Management Limited
1.79% · 14.88M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
10 filings tracked · 0 buys · 2 sells
| Name | Role | Stake |
|---|---|---|
| Kallam Reddy | Chairman of the Board & Member of the Management Council | 13.61% |
| Gunupati Prasad | Co-Chairman, MD & Member of Management Council | 13.07% |
| Deepak Sapra | CEO of API & Services & Member of Management Council | 0.01% |
| Motupalli Ramana | CEO of Branded Markets - India & Emerging Countries and Member of Management Council | 0.01% |
| Milan Kalawadia | Chief Commercial Officer of North America Generics | 0.01% |
| M S Sundar | Head of Global Manufacturing FTO Oral Solid Dosages & Operational Excellence | 0.00% |
| Bhethanabottla Phanimitra | Chief Information Officer & Member of the Management Council | 0.00% |
| Sushrut Kulkarni | Global Head of Integrated Product Development Organisation & Member of the Management Council | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-03-31 | M S Sundar | Head of Global Manufacturing FTO Oral Solid Dosages & Operational Excellence | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Gunupati Prasad | Co-Chairman, MD & Member of Management Council | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Kallam Reddy | Chairman of the Board & Member of the Management Council | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Deepak Sapra | CEO of API & Services & Member of Management Council | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Motupalli Ramana | CEO of Branded Markets - India & Emerging Countries and Member of Management Council | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Milan Kalawadia | Chief Commercial Officer of North America Generics | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Sushrut Kulkarni | Global Head of Integrated Product Development Organisation & Member of the Management Council | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Bhethanabottla Phanimitra | Chief Information Officer & Member of the Management Council | Initial Statement of Beneficial | 0 | -- |
| 2024-07-28 | Erez Israeli | CEO & Member of the Management Council | Intent to Sell (Form 144) | -327,500 | $16.46 |
| 2023-10-29 | Erez Israeli | CEO & Member of the Management Council | Intent to Sell (Form 144) | -25,000 | $13.09 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:11:49 · For reference only, not investment advice and not tailored to your situation.